ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

4-(6-Chloro-5-methyl-pyrimidin-4-yloxy)-piperidine-1-carboxylic acid isopropyl ester → 4-[6-(6-Methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic Acid Isopropyl Ester

HRID 116
ノート
印刷プレビュー

反応式

HRID 116 の反応式
Cc1c(Cl)ncnc1OC1CCN(C(=O)OC(C)C)CC1.Cc1nc(S(C)(=O)=O)ccc1N>C1COCCO1.CC(=O)O.CC(=O)O.CC(C)(C)[O-].CC(C)CN1CCN2CCN(CC(C)C)P1N(CC(C)C)CC2.[Na+].[Pd]>Cc1nc(S(C)(=O)=O)ccc1Nc1ncnc(OC2CCN(C(=O)OC(C)C)CC2)c1C
参加物反応条件実験手順出典と根拠反応ノート

参加物

7

反応物 2

HCID 114933574-(6-Chloro-5-methyl-pyrimidin-4-yloxy)-piperidine-1-carboxylic acid isopropyl esterHCID 510505272-Methyl-6-(methylsulfonyl)pyridin-3-amine

生成物 1

HCID 236492124-[6-(6-Methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic Acid Isopropyl Ester収率 54.09%

試薬・触媒・溶媒 4

HCID 23676156Sodium t-butoxide試薬
HCID 4144353
Palladium (II) acetate
触媒
HCID 45712432,8,9-Triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo(3.3.3)undecane触媒
HCID 312751,4-Dioxane溶媒

反応条件

温度
90 °C

実験手順

Sodium tert-butoxide (9.83 mL, 80.31 mmol) was added portionwise to isopropyl 4-(6-chloro-5-methylpyrimidin-4-yloxy)piperidine-1-carboxylate (10.50 g, 33.46 mmol) and 2-methyl-6-(methylsulfonyl)pyridin-3-amine (5.92 g, 31.79 mmol) in dioxane (160 mL) at 18ºC over a period of 1 minute under nitrogen. The reaction was degassed with vacuum / nitrogen (6 times) and 2,8,9-Triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo{3.3.3}undecane (0.238 mL, 0.67 mmol) and Palladium(II) acetate (0.075 g, 0.33 mmol) was added and the suspension was stirred at 90 °C for a further 2 hours. More 2,8,9-Triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo{3.3.3}undecane (0.238 mL, 0.67 mmol) and Palladium(II) acetate (0.075 g, 0.33 mmol) was added and the suspension was stirred at 90 °C for a further another 2 hours before being allowed to cool and stirred at room temperature overnight. The reaction was worked up with water (50 mL) and diluted with EtOAc (400 mL), and washed sequentially with water (100 mL) and saturated brine (50 mL). The organic layer was dried over Na2SO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography (330g column), elution gradient 0 to 50% EtOAc in DCM (rising quickly to 20% then more slowly to 50%). The impure fractions were collected and combined and purified again in exactly the same way. Pure fractions were evaporated to dryness to afford isopropyl 4-(5-methyl-6-(2-methyl-6-(methylsulfonyl)pyridin-3-ylamino)pyrimidin-4-yloxy)piperidine-1-carboxylate, EN02029-72-solid-1, as a yellow solid. This solid was recrystallised from MeOH (~ 50 mL) and the resultant solid filtered off and washed with cold MeOH (2 x 5 mL), Et2O (2 x 5 mL) then isohexane (2 x 5 mL). The solid, EN02029-72-solid-2 was combined with the product from EN02029-67-01 and the whole sample was named EN02029-72-01 (8.39 g) and submitted to the collection.

出典と根拠

ORDレコード
ord-3c40e6ac0b7c4653beac4f187a4bcda3
出典データセット
750 AstraZeneca ELN dataset
元リンク
出典を表示

反応ノート

読み込み中…

このページの内容参加物反応条件実験手順出典と根拠反応ノート